TG THERAPEUTICS, INC. Gain (Loss) on Extinguishment of Debt
TG THERAPEUTICS, INC. (TGTX) reported Gain (Loss) on Extinguishment of Debt of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-05
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was -$9.15M.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $0.00.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $0.00.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2025 was $0.00.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2024 was -$4.61M.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- TG THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 119 month | Gain (Loss) on Extinguishment of Debt 122 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | -$9.15M 10-Q · filed 2026-08-05 | -$9.15M derived: sum of 3 quarters · filed 2026-08-05 | -$9.15M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$9.15M 10-Q · filed 2026-05-06 | -$9.15M derived: sum of 2 quarters · filed 2026-05-06 | -$9.15M derived: sum of 3 quarters · filed 2026-05-06 | -$9.15M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$4.61M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | -$4.61M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | |||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |||||
| 2011-09-30 | $1.23M 10-Q · filed 2011-11-14 | $1.23M derived: sum of 2 quarters · filed 2011-11-14 | -$1.23M 10-Q · filed 2011-11-14 | -$1.38M 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $0.00 10-Q/A · filed 2011-09-14 | $0.00 10-Q/A · filed 2011-09-14 | -$159.07K 10-Q/A · filed 2011-09-14 | |||
| 2010-09-30 | $0.00 10-Q · filed 2011-11-14 | -$159.07K derived: sum of 2 quarters · filed 2011-11-14 | -$159.07K 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | -$159.07K 10-Q/A · filed 2011-09-14 | -$159.07K 10-Q/A · filed 2011-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |